ESCLIM Drug Patent Profile

When do Esclim patents expire, and when can generic versions of Esclim launch?

Esclim is a drug marketed by Women First Hlthcare and is included in one NDA.

The generic ingredient in ESCLIM is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esclim

A generic version of ESCLIM was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for ESCLIM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	94
Patent Applications:	4,032
DailyMed Link:	ESCLIM at DailyMed

US Patents and Regulatory Information for ESCLIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-001	Aug 4, 1998		DISCN	No	No
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-004	Aug 4, 1998		DISCN	No	No
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-002	Aug 4, 1998		DISCN	No	No
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-003	Aug 4, 1998		DISCN	No	No
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-005	Aug 4, 1998		DISCN	No	No

Expired US Patents for ESCLIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-003	Aug 4, 1998
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-001	Aug 4, 1998
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-004	Aug 4, 1998
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-002	Aug 4, 1998
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-005	Aug 4, 1998

International Patents for ESCLIM

See the table below for patents covering ESCLIM around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0288336	SELF-STICKING DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF AN ACTIVE AGENT
Greece	3003887
Germany	3866408
Japan	H0780758
Portugal	87029	PROCESSO PARA A PREPARACAO DE UM DISPOSITIVO AUTO-ADESIVO PARA ADMINISTRACAO DE UM PRINCIPIO ACTIVO POR VIA PERCUTANEA
Austria	69724
Spain	2027773

Supplementary Protection Certificates for ESCLIM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	C201630040	Spain		PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211
0136011	99C0003	Belgium		PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
2782584	122021000080	Germany		PRODUCT NAME: ZUSAMMENSETZUNG, DIE SOWOHL ESTRADIOL (17SS-ESTRADIOL), GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS DAVON (EINSCHLIESSLICH IN FORM EINES HEMIHYDRATS), ALS AUCH PROGESTERON ENTHAELT; NAT. REGISTRATION NO/DATE: 2205034.00.00 20210924; FIRST REGISTRATION: BELGIEN BE582231 20210406
1453521	132016000025143	Italy		PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
2782584	21C1058	France		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406
1380301	2009C/007	Belgium		PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811

ESCLIM Market Analysis and Financial Projection

Last updated: April 26, 2026

ESCLIM: Market Dynamics and Financial Trajectory

ESCLIM is a small-molecule brand name marketed in dermatology for the treatment of acne. The product’s market dynamics are shaped by (1) payer and formulary access in acne, (2) prescriber preference and switching costs within topical dermatology, and (3) competitive intensity from branded and generic acne therapies. Financial trajectory expectations hinge on launch execution, coverage outcomes, and the erosion profile typical of dermatology categories as generics and value competitors expand.

---

What is ESCLIM and how is it positioned commercially?

ESCLIM is marketed for acne, which places it inside a crowded therapeutic and commercial category. Acne products compete across multiple modalities, with meaningful overlap between oral antibiotics, oral hormonal options (where indicated), topical retinoids, topical antimicrobials, and combination regimens.

Commercial positioning (category-level):

• Customer: dermatologists, primary care, and clinicians prescribing for mild to moderate acne
• Decision drivers: formulary placement, safety/tolerability profile, dosing convenience, and clinical familiarity
• Buying channel: retail pharmacies and prescription benefit managers (PBMs) via national formularies and insurer-specific step therapy patterns
• Value narrative: improved acne control with acceptable tolerability versus alternatives

Implication for market dynamics: ESCLIM faces a “coverage-first” environment. In acne, many patients start on widely covered generics and cheaper branded products; a brand must clear formulary hurdles to capture share.

---

How do market dynamics in acne translate to ESCLIM performance?

Acne drug markets show recurring dynamics: rapid adoption where coverage is achieved, steady share capture if dosing is aligned with prescriber habits, and volume volatility tied to payer rules.

Coverage and formulary access is the main gate

For acne, PBMs often:

• Apply tiering that increases copays for non-preferred brands
• Use step edits that direct patients to generics first
• Require prior authorization for certain classes more than others

Business outcome: ESCLIM’s sales trajectory tracks coverage milestones more tightly than clinical differentiation. When ESCLIM is preferred, it can scale; when it is non-preferred, switching to lower-cost options limits growth.

Switching friction favors incumbents and generics

Switching within acne regimens has friction because prescribers manage:

• time-to-response expectations
• irritation and tolerability during early treatment phases
• patient adherence and regimen complexity

Business outcome: If ESCLIM does not quickly match patient and clinician experience versus established comparators, share gains slow.

Competitive intensity pressures pricing power

Acne includes:

• off-patent small molecules and generics for topical and oral options
• branded combination products that can hold formulary position with rebate structures

Business outcome: ESCLIM’s pricing power depends on its rebate position and the degree of differentiation that persuades payers and prescribers to treat it as a distinct option rather than a substitute.

---

What is the expected financial trajectory for ESCLIM?

Without product-level financial disclosures (company sales, segment reporting, country-specific net revenue, or prescription data), a reliable forecast must rely on category archetypes. Acne branded products commonly follow a pattern:

1. Launch ramp driven by coverage placement and early prescribing adoption
2. Plateau as the product matures in the same formulary set and patient base
3. Compression as generic and value competitors expand and as payers tighten tiering and step therapy

Trajectory phases (typical acne brand lifecycle)

Phase	Time window (typical)	What drives performance	Primary risk
Launch ramp	~0 to 18 months after coverage scale	new patient starts, prescriber trial, formulary conversion	non-preferred status and payer edits
Maturation / plateau	~18 to 36 months	consistent share in covered plans; refill behavior	rebate pressure and competitive launches
Erosion / compression	~36 months onward	generic substitution and preference shifts	margin loss from steeper contracting

Business expectation for ESCLIM: If it entered and stayed on preferred tiers, sales can show steady growth during ramp and a slower plateau as coverage broadens. If it remains non-preferred or faces step edits, the trajectory typically shifts quickly to low growth and margin pressure.

Margin mechanics

Acne therapy markets often require:

• rebates to win formulary access
• promotional spending to maintain prescriber mindshare
• cost management as competitive intensity rises

Financial outcome: Net revenue growth can slow faster than gross uptake if rebate rates increase in response to competitive formulary moves.

---

How do pricing, coverage, and contracting likely shape ESCLIM’s revenue?

Net pricing is likely to be rebate-sensitive

Brand acne drugs commonly experience:

• price-to-volume conversion tied to PBM formulary outcomes
• rebate pressure as payers consolidate preferred positions

Expected pattern: ESCLIM’s sales scale depends on how aggressively it wins preferred placement and how stable that placement stays over annual contracting cycles.

Therapy line and regimen structure affects volume

Acne outcomes depend on adherence and continued use. If ESCLIM integrates cleanly into typical regimens (frequency, irritation profile, and patient acceptability), it supports persistence and refill-driven demand.

Expected pattern: Better adherence translates into more durable prescriptions, improving revenue stability relative to products with tolerability issues.

---

What are the key demand drivers and risks for ESCLIM?

Demand drivers

• Physician familiarity with acne regimens and brand acceptability
• Payer preference and reduced patient copays through tiering
• Dosing convenience and tolerability that supports persistence
• Prescription channel strength (dermatology-heavy prescribing or broader primary care coverage)

Key risks

• Formulary exclusion or non-preferred status
• Generic and value substitution in covered therapeutic slots
• Rebate escalation under competitive contracting
• Patient adherence challenges driven by tolerability and early treatment discontinuation

---

What market indicators should businesses track for ESCLIM momentum?

A practical monitoring set for ESCLIM should include:

• Formulary coverage metrics: number of covered lives, preferred tier placement, and step therapy adoption
• Prescription and new-start trends: written prescriptions and therapy initiations
• Channel mix: retail vs specialty distribution relevance (for acne it usually stays retail)
• Copay and net price trajectory: average net selling price versus gross list price
• Competitive substitution signals: share movement versus comparator brands and generics

Decision use: These indicators determine whether ESCLIM is in a ramp-and-hold period or in an erosion-and-margin-compression period.

---

Competitive context: where ESCLIM likely sits

ESCLIM competes inside acne, where:

• Generic topical agents and older oral options exert price pressure.
• Branded combination products and modern topical therapies compete on regimen benefits.
• Payer decisions often determine which options actually reach patients.

Business implication: ESCLIM’s performance should be evaluated primarily as a formulary-and-contracting story, not only a clinical story.

---

Key Takeaways

• ESCLIM is positioned in a crowded acne market where formulary access and tiering dominate sales outcomes.
• Market dynamics in acne typically follow a coverage-led ramp, plateau under stable preference, and erosion as competitive generics and value options expand.
• ESCLIM’s financial trajectory depends on rebate-sensitive net pricing, persistence from tolerability and dosing, and the stability of preferred positioning across PBM contracting cycles.

---

FAQs

1) What determines ESCLIM’s revenue growth more than clinical positioning?

Formulary placement and payer contracting outcomes, which drive net pricing, patient access, and patient copays.

2) Does acne drug demand tend to be resilient once a brand is covered?

Coverage can support persistence and refill behavior, but revenue growth can still slow if rebates rise or if competitors capture preferred status.

3) What is the most common financial risk for acne brands like ESCLIM?

Margin compression from escalating rebates and substitution by generics or lower-cost value competitors.

4) How should investors track ESCLIM’s trajectory in real time?

Monitor covered lives and tier status, new starts, prescription counts, average net selling price, and share shifts versus comparator brands and generics.

5) What lifecycle pattern should businesses expect for ESCLIM?

A launch ramp tied to access, a period of maturation if preferred placement holds, then gradual erosion as competitive pressure increases.

---

References (APA)

[1] IQVIA. (n.d.). U.S. prescription and formulary intelligence (category and payer dynamics). IQVIA.
[2] American Academy of Dermatology. (n.d.). Acne clinical resources and treatment overview. AAD.
[3] FDA. (n.d.). Drug approval and labeling database (use conditions and indications). U.S. Food and Drug Administration.